作者: T. W. Higenbottam , J. Wallwork
DOI: 10.1007/978-94-009-0711-9_38
关键词:
摘要: Combined heart—lung transplantation has advanced from an innovative surgical technique to a clinical treatment of severe pulmonary vascular disease1, chronic end-stage lung disease2, and cystic fibrosis3. Developments in organ preservation4 (Chapters 7 35) careful selection recipients donors, together with active investigation rejection using transbronchial biopsy (TBB), have led effective use limited donor resources.